TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05501262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Image (ultrasound and fluoroscopic guided) cryoablation will be performed of the Morton's neuroma after nerve block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block
Description: Ultrasound and fluoroscopic guided nerve block.
Study: NCT05569811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab deruxtecan
Description: HER3-DXd will be administered as Lyo-DP, a sterile lyophilized powder in a dose of 5.6 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab deruxtecan
Description: HER3-DXd will be administered as Lyo-DP, a sterile lyophilized powder in a dose of 5.6 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Anthracycline/taxane-based neoadjuvant regimen recommended by the NCCN or local guidelines. i.e. EC or AC (epirubicin 90 mg/m2 or doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 14 or 21 days) followed by weekly paclitaxel 80mg/m2 during 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole and LHRH will be used following SmPC specifications, according to standard therapy and clinical studies
Study: NCT05753033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SR750 tablet
Description: Ascending single and multiple doses of SR750 orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ascending single and multiple doses of placebo orally
Study: NCT04764162

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Choline
Description: 1000 mg (2 x 500 mg) choline bitartrate capsules (over-the-counter supplement)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Choline
Description: 1000 mg (2 x 500 mg) choline bitartrate capsules (over-the-counter supplement)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Choline-matched 1000 mg (2 x 500 mg) placebo (maltodextrin) capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Choline-matched 1000 mg (2 x 500 mg) placebo (maltodextrin) capsules
Study: NCT05217888

Intervention type: DEVICE
Intervention: Sentinel
Description: cerebral protection devices during transfemoral transcatheter aortic valve replacement
Study: NCT06534944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: NR 1g daily for 4 weeks
Study: NCT05663723

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group with the IV and V LED board
Description: Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in two wavelengths: 42 red (660nm) and 42 infrared (850nm); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
Study: NCT06177431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monepantel
Description: Monepantel is provided to individuals living with ALS/MND as a white oval tablet to be administered once a day following meals
Study: NCT06336434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV LA 600mg
Description: 600mg (2mL) IM injection
Study: NCT06505265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral; Tablet
Study: NCT05768555

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole body vibration intervention at 40 Hz
Description: Whole body vibration intervention will be performed with the Power Plate Pro 5 device (Power Plate International, London, UK). Whole body vibration training will be performed at a frequency of 40 Hz. Individuals will perform; static squat, dynamic toe raise, static abduction and dynamic squat exercises in both hips on a vibrating platform. All exercises will consist of 45 seconds of vibration and 15 seconds of rest. Each exercise will be repeated three times. Total intervention time will be 15 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole body vibration intervention at 25 Hz
Description: Whole body vibration intervention will be performed with the Power Plate Pro 5 device (Power Plate International, London, UK). Whole body vibration training will be performed at a frequency of 25 Hz. Individuals will perform; static squat, dynamic toe raise, static abduction and dynamic squat exercises in both hips on a vibrating platform. All exercises will consist of 45 seconds of vibration and 15 seconds of rest. Each exercise will be repeated three times. Total intervention time will be 15 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole body vibration intervention at 0 Hz
Description: Whole body vibration intervention will be performed with the Power Plate Pro 5 device (Power Plate International, London, UK). Whole body vibration training will be performed at a frequency of 0 Hz. Individuals will perform; static squat, dynamic toe raise, static abduction and dynamic squat exercises in both hips on a vibrating platform. All exercises will consist of 45 seconds of vibration and 15 seconds of rest. Each exercise will be repeated three times. Total intervention time will be 15 minutes.
Study: NCT06648096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib starting at 20 mg (weeks 1-2), escalating to 30 mg after two weeks (weeks 3-4) and escalating to 40 mg after one month (week 5 - thereafter) if no hematologic or other relevant toxicities are observed (CTCAE V5.0 \< grade 2)
Study: NCT06649552

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Psychiatric and psychological diagnostic tests
Description: French validation of the SPI-CY
Study: NCT05663723

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group with the IV, V and Violet LED board
Description: Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra model (Cosmedical) in a predefined cycle, with the combination of light emitters in three wavelengths: 18 red (660nm), 18 infrared (850nm) and 36 violet (420nm). ); LED blanket in the size of 10x12 cm; average power of each LED: 5mW; operating mode: continuous; polarization: random; irradiance at the opening of each LED: 25mW/cm2; opening diameter of each LED: 10mm; application time: 1 session of 20 minutes; power per LED: 30mW; radiant exposure: 36J/cm2 during 20 minutes of application. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control group with LED board without emitting light
Description: Applications of the LED board will be performed daily for 20 minutes on each extremity (foot soles), until the last day of chemotherapy treatment. The sequential LED treatments will be administered by the Sportllux Ultra (Cosmedical) model without the light emitting combination. LED blanket in the size of 10x12 cm and application time: 1 session of 20 minutes. Tissue from the lower limb extremities will come into contact with the LED panel during treatment to ensure even delivery of photobiomodulation. The panels are large enough to more than cover the entire edge area at one time during application.
Study: NCT05760573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Wellness Program (FWP)
Description: The FWP will consist of the following general format: (1) 8 weekly 60-minute summer workshops; (2) 4 booster workshops throughout the year; and (3) 2-3 outreach text messages per week for 10 months.
Study: NCT04941378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTL38
Description: One time infusion of OTL38
Study: NCT04491253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support for diabetes self-management
Description: Four individualized intervention sessions, every two weeks with a duration of 40 minutes.
Study: NCT05564793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pre-implantation planning
Description: ECGi mapping using the CE marked Amycard 01C device and a contrast enhanced CT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Post-implantation assessment
Description: ECGi mapping using the CE marked Amycard 01C device and a non-contrast CT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Post-implantation assessment
Description: ECGi mapping using the CE marked Amycard 01C device and a non-contrast CT
Study: NCT04956770

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation surgery
Description: The intervention involves the implantation of:~* a neurostimulator: the Activa® RC from Medtronic~* a stimulation electrode paddle array: the Specify™ SureScan® 5-6-5 from Medtronic
Study: NCT04671173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of the Intra-Compartmental Pressure with the MY01 device
Description: All Participants will be monitored for clinical signs of symptoms of ACS, including the 7 Ps at a minimum of every 4-6 hours.~The Intra-Compartmental Pressure of the anterior compartment of the leg will be monitored with the MY01 device. The device should be inserted five centimeters (5 cm) from the fracture, if possible, in the muscle belly. The affected limb will then be splinted in a standard U-slab with no pressure on the monitored device.
Study: NCT05914324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phefumla device
Description: The Phefumla device uses the Motorola Moto G Power mobile phone. The device utilizes an Android 10 operating system and has 64 gigabyte memory with 4 gigabyte random access memory (RAM). The battery is a 5000 milliampere lithium polymer rechargeable battery, which should last at least 24 hours with minimal phone use. Data can be stored on the device and integration with information systems is planned. The reflectance sensor works on a variety of body parts including the finger, toe, and forehead.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LB-01 device
Description: The LB-01 probe uses transmissive oximetry with the light-emitting diode (LED) and photodetector (PD) positioned opposed to one another when placed on body tissues like fingers, and is used with the Acare pulse oximeter device. The LB-01 probe is an elongated clip sensor with an offset optics location near the hinge, permitting stable positioning on the child's big toe. By incorporating softer hollow silicone pads this design grasps the foot while placing the optics over the toe, to minimize movement artifact, an important issue for child measurements. The soft pads allow comfortable use across the smaller foot of neonates, and the design remains similar enough to a conventional finger sensor that it can be used on adult fingers as well.
Study: NCT06264310

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R2R01
Description: Pharmaceutical Form: sterile 2R vials containing 10 mg of R2R01 for SC injection.
Study: NCT05638035

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonografi, Sarcopenia measurement, Zebris
Description: The rectus femoris muscle thickness of the participants will be performed in B mode via USG (Mindray-UMT 200,USA) with a multifrequency (7-15 MHz) linear probe and the measurement will be reported.~TANITA for sarcopenia, hand grip strength and walking speed will be evaluated.~Gait time-distance parameters and Static balance COP parameters (COP speed (cm/s) and COP length (cm)) will be recorded using Zebris™ FDM-2.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonografi, Sarcopenia measurement, Zebris
Description: The rectus femoris muscle thickness of the participants will be performed in B mode via USG (Mindray-UMT 200,USA) with a multifrequency (7-15 MHz) linear probe and the measurement will be reported.~TANITA for sarcopenia, hand grip strength and walking speed will be evaluated.~Gait time-distance parameters and Static balance COP parameters (COP speed (cm/s) and COP length (cm)) will be recorded using Zebris™ FDM-2.
Study: NCT06324305

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy (PPV) and drainage of subretinal fluid
Description: Drainage of subretinal fluid during Pars Plana Vitrectomy in patients with rhegmatogenous retinal detachment (RRD)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy (PPV) and drainage of subretinal fluid
Description: Drainage of subretinal fluid during Pars Plana Vitrectomy in patients with rhegmatogenous retinal detachment (RRD)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy (PPV) and drainage of subretinal fluid
Description: Drainage of subretinal fluid during Pars Plana Vitrectomy in patients with rhegmatogenous retinal detachment (RRD)
Study: NCT06264310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R2R01
Description: Pharmaceutical Form: sterile 2R vials containing 10 mg of R2R01 for SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R2R01
Description: Pharmaceutical Form: sterile 2R vials containing 10 mg of R2R01 for SC injection.
Study: NCT06166641

Intervention type: PROCEDURE
Intervention: Surgical procedure at operating room
Description: A surgical procedure in an operating room is a medical intervention that involves making incisions or using minimally invasive techniques to treat a specific condition or perform a diagnostic procedure. The operating room, also known as the operating theater or surgical suite, is a sterile environment specifically designed to minimize the risk of infection and ensure the safety of both the patient and the surgical team.
Study: NCT05183555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATOC PET/CT
Description: 68Ga-DOTATOC PET/CT will be recorded the following day of 18F-FDG PET/CT if patient signed the consent
Study: NCT05837026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Outreach Intervention (EOI) plus Care as Usual (CAU)
Description: The EOI will contain four main components: safety planning, caring contacts, care engagement, and risk assessment.~Outreach (via phone or text messaging) from Samaritans staff will be conducted every week of the 12 week intervention. Conversations will use a standardized phone script to (a) conduct a risk assessment, (b) develop and review a list of coping skills to use if the participant has suicidal thoughts, and (c) discuss plans for receiving mental health care. Samaritans staff will also send a caring text message or email at least once per week.~Participants will also receive standard care that hospitals provide to patients who present with suicidal thoughts.

Intervention type: OTHER
Group type: OTHER
Intervention: Care as Usual (CAU)
Description: Participants will receive standard care that hospitals provide to patients who present with suicidal thoughts.
Study: NCT05033561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nOPV2
Description: Novel Oral Poliomyelitis Type 2 Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nOPV2
Description: Novel Oral Poliomyelitis Type 2 Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: nOPV2
Description: Novel Oral Poliomyelitis Type 2 Vaccine
Study: NCT05455996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: MDMA-assisted therapy
Study: NCT06431256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD200 methylphenidate hydrochloride capsules
Description: Doses: 20mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLD200 methylphenidate hydrochloride capsules
Description: Doses: 20mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo HLD200 capsules
Description: Doses: 20mg capsules
Study: NCT06391086

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviFUS® Neuronavigation-guided focused ultrasound system
Description: The treatment protocol consists of once daily treatment for consecutive five tFUS sessions.
Study: NCT05683262

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection
Description: Ultrasound guidance is used for correct visualization of injection site, and so obtained more successful results. Patients are placed in the prone position with a pillow under the abdomen to flatten the lumbar curvature. Lower extremities should be internally rotated while feet are inverted to help flatten the gluteal region. Injection site is cleaned thrice with povidone iodine %10 solution and covered with sterile drapes. Ultrasonography gel was applied on the probe and the probe was wrapped with a transparent thin sheath and cleaned with povidone iodine. Sterile gel is applied on the skin. The sacrococcygeal ligament, the sacrococcygeal and intercoccygeal joints were visualized. The sacrococcygeal and/or intercoccygeal joints were entered using the in-plane technique with a 23 gauge 6 cm long needle. When it was seen that the needle tip was inside the joint, 3 cc of 2% lidocaine + 1 cc betamethasone solution was injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided coccygeal nerve block
Description: Patients are placed in the prone position with a pillow under the abdomen. Lower extremities are internally rotated while feet are inverted. Injection site and the probe are cleaned thrice with povidone iodine %10 solution. Sterile gel is applied. The prob was placed on coccygeal cornu and the coccygeal nerve was visualized superomedial to the CC in the subcutaneous tissue layer. Hydrodissection was made by administering 5 ml of 5% dextrose + 1 ml of 2% lidocaine via an in-plane approach with a 23 gauge 6 cm long needle, targeting the short axes of the bilateral coccygeal nerves.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided sacrococcygeal and/or intercoccygeal joint injection after coccygeal nerve block
Description: After the coccygeal nerve block, when the pain with palpation of the coccygeal region was reduced by at least 50%, the sacrococcygeal ligament, sacrococcygeal and intercoccygeal joints were visualized.The sacrococcygeal and/or intercoccygeal joints were entered using the in-plane technique with a 23 gauge 6 cm long needle. When the needle tip was inside the joint, 3 cc of 2% lidocaine + 1 cc betamethasone solution was injected.
Study: NCT05018273

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VB10.NEO
Description: The personalized vaccine VB10.NEO vaccine is given in combination with the PD-L1 inhibitor atezolizumab.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VB10.NEO
Description: The personalized vaccine VB10.NEO vaccine is given in combination with the PD-L1 inhibitor atezolizumab.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VB10.NEO
Description: The personalized vaccine VB10.NEO vaccine is given in combination with the PD-L1 inhibitor atezolizumab.
Study: NCT06168604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Identification and Communication Toolkit
Description: The Pain Identification and Communication Toolkit (PICT) is a multicomponent (6 module) intervention for family caregivers of persons with Alzheimer's disease and related dementias (ADRD). PICT consists of 4 weekly telephone sessions (30-60 minutes each) delivered by a trained interventionist

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Health Promotion Program
Description: The attention control (AC) condition is referred to as the Health Promotion Program (HPP). The HPP will consist of 4 weekly telephone sessions (30-60 minutes each) but focus on caregiver health promotion topics, such as nutrition, exercise, and sleep.
Study: NCT05381038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QPOP
Description: QPOP is a mechanism-agnostic platform for optimizing drug selection. QPOP uses a quadratic equation to describe the patient-specific drug-drug interaction space based solely on experimentally derived drug-response data on individual patient's tissue sample, from which optimal drug combinations can be identified. Drug selection via QPOP allows for identification of an optimal combination therapy without the need for exhaustive testing of every combination. The first stage of the trial aims to generate a personalised QPOP drugs list for each participant based on experimentally derived data from ex vivo testing in the participant's tissue sample. Optimal drugs from a pre-specified drug pool will be recommended by the QPOP team.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CURATE.AI
Description: CURATE.AI - a small data, AI-derived technology platform based on this discovery - allows personalised guidance of an individual's dose modulations based only on that individual's data. Additionally, CURATE.AI is mechanism-independent, and dynamically adapts to changes experienced by the participant, providing dynamic dose optimisation throughout the duration of the participant's treatment.~The second stage of the trial aims to obtain a personalised CURATE.AI profile for each participant, based on their phenotypic response to a set of drug doses from the drug combinations with azacitidine identified and recommended by the QPOP team. The doses will be recommended by the CURATE.AI team, when relevant to the clinical decision-making process. Once an actionable profile is obtained, dose recommendations are based on the profile and aimed to treat the participant.~The maximum period of involvement with this study when azacitidine may be adjusted by CURATE.AI is 18 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine + docetaxel
Description: Azacitidine subcutaneous injection Day 1, 2 and Day 8, 9 + 30 mg/m2 docetaxel intravenously Day 1 and 8~Each chemotherapy cycle will be 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine + paclitaxel
Description: Azacitidine subcutaneous injection Day 1, 2 and Day 8, 9 + 80 mg/m2 paclitaxel intravenously Day 1 and 8~Each chemotherapy cycle will be 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine + irinotecan
Description: Azacitidine intravenously subcutaneous injection Day 1, 2 and Day 8, 9 + 100 mg/m2 irinotecan intravenously Day 1 and 8.~Each chemotherapy cycle will be 21 days.